AANEM Meeting Highlights Advances in Gene Therapies for Muscular Dystrophies

The recent AANEM annual meeting in Savannah, Georgia, highlighted groundbreaking advancements in gene therapies for muscular dystrophies, focusing on patient selection and the challenges of pre-existing immunity to AAV vectors. Dr. Melissa Spencer emphasized the need for standardized assessment methods to identify suitable candidates for innovative treatments, particularly for Duchenne muscular dystrophy (DMD). With ongoing research and collaboration, the future of muscular dystrophy treatment looks promising, offering hope to affected individuals and their families.